Decreased blood flow with increased metabolic activity: A novel sign of pancreatic tumor aggressiveness

Clinical Cancer Research

Volumn 15, Issue 17, 2009, Pages 5511-5517

  Komar, Gaber ^a   Kauhanen, Saila ^a   Liukko, Kaisa ^a   Seppänen, Marko ^a   Kajander, Sami ^a   Ovaska, Jari ^a   Nuutila, Pirjo ^a,b   Minn, Heikki ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; OXYGEN 15;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLISM; PANCREAS BLOOD FLOW; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREAS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; REGIONAL BLOOD FLOW; TUMOR MARKERS, BIOLOGICAL;

EID: 69949109921     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0414     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-1057
3. Twombly R. Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. J Natl Cancer Inst 2008;100:1670-1671
4. Reuter SR, Redman HC, Bookstein JJ. Differential problems in the angiographic diagnosis of carcinoma of the pancreas. Radiology 1970;96:93-99
5. Lang SA, Schachtschneider P, Moser C, et al. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther 2008;7:3509-3518
6. Longo R, Cacciamani F, Naso G, Gasparini G. Pancreatic cancer: from molecular signature to target therapy. Crit Rev Oncol Hematol 2008;68:197-211.
7. Miles KA, Hayball MP, Dixon AK. Measurement of human pancreatic perfusion using dynamic computed tomography with perfusion imaging. Br J Radiol 1995;68:471-475
8. Bize PE, Platon A, Becker CD, Poletti PA. Perfusion measurement in acute pancreatitis using dynamic perfusion MDCT. AJR Am J Roentgenol 2006;186:114-118 (Pubitemid 46100370)
9. Sofuni A, Iijima H, Moriyasu F, et al. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol 2005;40:518-525 (Pubitemid 40823288)
10. Bali MA, Metens T, Denolin V, De M, Deviere V, Matos J. Pancreatic perfusion: noninvasive quantitative assessment with dynamic contrast-enhanced MR imaging without and with secretin stimulation in healthy volunteers - initial results. Radiology 2008;247:115-121
11. Kubo S, Yamamoto K, Magata Y, et al. Assessment of pancreatic blood flow with positron emission tomography and oxygen-15 water. Ann Nucl Med 1991;5:133-138
12. Anderson H, Price P. Clinical measurement of blood flow in tumours using positron emission tomography: a review. Nucl Med Commun 2002;23:131-138 (Pubitemid 34547900)
13. de Langen AJ, Lubberink M, Boellaard R, et al. Reproducibility of tumor perfusion measurements using 15O-labeled water and PET. J Nucl Med 2008;49:1763-1768
14. Lodge MA, Jacene HA, Pili R, Wahl RL. Reproducibility of tumor blood flow quantification with 15O-water PET. J Nucl Med 2008;49:1620-1627
15. Rajendran JG. Positron emission tomography imaging of blood flow and hypoxia in tumors. In: Mankoff DA, editor. Cancer drug discovery and development in vivo imaging of cancer therapy. Totowa (NJ): Humana Press, Inc.; 2008, p. 47-71.
16. Miles KA, Williams RE. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging 2008;8:81-86
17. Teras M, Tolvanen T, Johansson JJ, Williams JJ, Knuuti J. Performance of the new generation of whole-body PET/CT scanners: Discovery STE and Discovery VCT. Eur J Nucl Med Mol Imaging 2007;34:1683-1692 (Pubitemid 47476933)
18. Komar G, Seppanen M, Eskola O, et al. 18FEF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944-1951
19. Blomqvist G. On the construction of functional maps in positron emission tomography. J Cereb Blood Flow Metab 1984;4:629-632 (Pubitemid 15222309)
20. Liukko KE, Oikonen V, Tolvanen T, et al. Noninvasive estimation of subcutaneous and visceral adipose t i ssue blood f low by using 15OH2O PET with image derived input functions. Open Med Imaging J 2007;1:7-13.
21. Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008;35:2320-2333
22. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277-2285
23. Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA. Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res 2002;8:2109-2115
24. D'Onofrio M, Martone E, Malago R, et al. Contrast-enhanced ultrasonography of the pancreas. JOP 2007;8:71-76
25. Park MS, Klotz E, Kim MJ, et al. Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology 2009;250:110-117
26. Tajima Y, Matsuzaki S, Furui J, Isomoto I, Hayashi K, Kanematsu T. Use of the time-signal intensity curve from dynamic magnetic resonance imaging to evaluate remnant pancreatic fibrosis after pancreaticojejunostomy in patients undergoing pancreaticoduodenectomy. Br J Surg 2004;91:595-600.
27. Coenegrachts K,Van Steenbergen W, De Keyzer F, et al. Dynamic contrast-enhanced MRI of the pancreas: initial results in healthy volunteers and patients with chronic pancreatitis. J Magn Reson Imaging 2004;20:990-997 (Pubitemid 39577901)
28. Lee SS, Byun JH, Park BJ, et al. Quantitative analysis of diffusion-weighted magnetic resonance imaging of the pancreas: usefulness in characterizing solid pancreatic masses. J Magn Reson Imaging 2008;28:928-936
29. Wells P, Jones T, Price P. Assessment of interand intrapatient variability in C15O2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers. Clin Cancer Res 2003;9:6350-6356 (Pubitemid 38031819)
30. Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 2003;30:274-280 (Pubitemid 36686847)
31. Hirasawa H, Tsushima Y, Hirasawa S, et al. Perfusion CT of breast carcinoma: arterial perfusion of nonscirrhous carcinoma was higher than that of scirrhous carcinoma. Acad Radiol 2007;14:547-552 (Pubitemid 46551751)
32. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-509
33. Groves AM, Wishart GC, Shastry M, et al. Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT. Eur J Nucl Med Mol Imaging 2009;36:416-421
34. Hermans R, Meijerink M, Van den BW, Rijnders A, Weltens C, Lambin P. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1351-1356 (Pubitemid 37443976)
35. Smalley KS, Brafford PA, Herlyn M. Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Semin Cancer Biol 2005;15:451-459 (Pubitemid 41318045)
36. Hosoki T. Dynamic CT of pancreatic tumors. AJR Am J Roentgenol 1983;140:959-965
37. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18
38. Kindler HL. A double-blind, placebo-controlled, randomized phase III trial of gemsitabine (G) plus bevacizumab versus gemsitabine plus placebo (P) in patients with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). In: Niedzwiecki D, editor. 25 no. 18S ed. 2007.
39. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007;67:2729-2735
40. Stockmann C, Doedens A, Weidemann A, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008;456:814-818
41. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79-83. (Pubitemid 28107907)
42. Zimny M, Buell U, Diederichs CG, Reske SN. False-positive FDG PET in patients with pancreatic masses: an issue of proper patient selection? Eur J Nucl Med 1998;25:1352.
43. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999;40:1784-1791 (Pubitemid 29523570)
44. Kroep JR, Van Groeningen CJ, Cuesta MA, et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer: a comparison of different analytical methods. Mol Imaging Biol 2003;5:337-346
45. Krak NC, Hoekstra OS, Lammertsma AA. Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. Eur J Nucl Med Mol Imaging 2004;31:103-111